Enhancing Duloxetine With Mirogabalin for Treating Taxane-Induced Peripheral Neuropathy in Advanced Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Neurology

Background:

• Taxane chemotherapy for advanced lung cancer frequently causes chemotherapy-induced peripheral neuropathy (CIPN).
• CIPN can lead to dose reductions, impacting treatment efficacy, and lacks established treatments.
• Duloxetine is a common supportive therapy, but its effectiveness for severe CIPN is limited.

Purpose of the Study:

• To evaluate the efficacy of mirogabalin as an add-on therapy for advanced lung cancer patients experiencing CIPN.
• To assess pain reduction in patients inadequately managed by duloxetine alone.

Main Methods:

• A retrospective observational cohort study was conducted.
• 14 advanced lung cancer patients receiving taxane chemotherapy and duloxetine were treated with add-on mirogabalin.
• Pain was assessed using the Numerical Rating Scale (NRS), with statistical analysis via Wilcoxon's signed rank-sum test.

Main Results:

• The median NRS pain score significantly decreased from 5.5 to 4.0 after mirogabalin administration (P = 0.041).
• Mirogabalin demonstrated a statistically significant reduction in CIPN-related pain.

Conclusions:

• Adding mirogabalin to duloxetine is a promising strategy for alleviating CIPN in advanced lung cancer patients on taxane therapy.
• These findings support further clinical investigation and potential integration into practice for CIPN management.